Overview

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of HemaMax in healthy male and female volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Neumedicines Inc.
Collaborator:
Department of Health and Human Services